Automated Synthesis of Radiopharmaceuticals: Technology, Applications, and Regulatory Perspectives.

Area of Science:

• Radiochemistry
• Nuclear Medicine
• Pharmaceutical Sciences

Background:

• Automated synthesis of radiopharmaceuticals has evolved significantly since early tracers like [18F]FDG.
• Initial development focused on radioisotope labeling, high yields, and purification methods like HPLC.
• The primary goals were radiation safety and process reproducibility.

Purpose of the Study:

• To review the historical development of automated radiopharmaceutical synthesis modules.
• To highlight advancements in radioisotope labeling, particularly for metallic radioisotopes.
• To discuss how recent automated processes meet current Good Manufacturing Practice (GMP) regulations.

Main Methods:

• Review of historical and recent literature on automated radiopharmaceutical synthesis.
• Analysis of chemical processes, purification techniques (e.g., solid-phase extraction), and yield optimization.
• Examination of regulatory compliance, specifically GMP standards for trackability and reproducibility.

Main Results:

• Significant improvements in radiochemical yields and purity have been achieved over time.
• Newer automated modules are optimized for metallic radioisotope labeling, offering high efficiency.
• Recent processes incorporate simplified synthesis and robust controls to comply with GMP.

Conclusions:

• Automated synthesis has progressed from basic labeling to complex, regulated processes.
• Modern radiopharmaceutical synthesis prioritizes efficiency, purity, safety, and regulatory adherence.
• The development trajectory ensures reliable and reproducible production of radiopharmaceuticals for clinical use.